The anti-diabetic PPARγ agonist Pioglitazone inhibits cell proliferation and induces metabolic reprogramming in prostate cancer.

Saved in:
Bibliographic Details
Title: The anti-diabetic PPARγ agonist Pioglitazone inhibits cell proliferation and induces metabolic reprogramming in prostate cancer.
Authors: Atas, Emine1,2,3 (AUTHOR) emine.atas@meduniwien.ac.at, Berchtold, Kerstin4 (AUTHOR), Schlederer, Michaela1 (AUTHOR), Prodinger, Sophie4 (AUTHOR), Sternberg, Felix5,6 (AUTHOR), Pucci, Perla7 (AUTHOR), Steel, Christopher7 (AUTHOR), Matthews, Jamie D.7 (AUTHOR), James, Emily R.7 (AUTHOR), Philippe, Cécile3 (AUTHOR), Trachtová, Karolína2,8 (AUTHOR), Moazzami, Ali A.9 (AUTHOR), Artamonova, Nastasiia10 (AUTHOR), Melchior, Felix10 (AUTHOR), Redmer, Torben11 (AUTHOR), Timelthaler, Gerald12 (AUTHOR), Pohl, Elena E.5 (AUTHOR), Turner, Suzanne D.7,13 (AUTHOR), Heidegger, Isabel10 (AUTHOR), Krueger, Marcus14 (AUTHOR)
Source: Molecular Cancer. 5/5/2025, Vol. 24 Issue 1, p1-26. 26p.
Database: Academic Search Ultimate
Full text is not displayed to guests.
Description
ISSN:14764598
DOI:10.1186/s12943-025-02320-y